跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ELREXFIO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ELREXFIO
Authorized
STANDARD
ELREXFIO
Pfizer Canada Ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
66f093f3460950a6
Company
Pfizer Canada Ulc
Type
Standard
Approval Details
Approval Id
66f093f3460950a6
Drug Approval Canada Name
ELREXFIO
Product Name
ELREXFIO
Status
Marketed
Status Date
2024-01-23
Original Market Date
2024-01-23
Din
02543559
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
08:18.24
Atc Original
L01FX32 ELRANATAMAB
Atc Name
l 01 fx 32
Aig Number
0165382001
Company Name
Pfizer Canada Ulc
Company Address
17300 Trans-Canada Highway, Kirkland, Quebec, Canada, H9J 2M5
Company Detail Path
/organization/pfizer-canada-ulc
Company Information
Pharmaceutical Company Name
Pfizer Canada Ulc
Country Name
Canada
Province Name
Quebec
City Name
kirkland,quebec,country_ca
Address
17300 rte Transcanadienne
Active Ingredients
ELRANATAMAB
44 MG / 1.1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
66f093f3460950a6
Type
Standard
Back to Health Canada Approvals